Outer surface protein C (OspC) is one of the major lipoproteins expressed on the surface of Borrelia burgdorferi during tick feeding and the early phase of mammalian infection. OspC is required for B. burgdorferi to establish infection in both immunocompetent and SCID mice and has been proposed to facilitate evasion of innate immune defenses. However, the exact biological function of OspC remains elusive. In this study, we showed that the ospC-deficient spirochete could not establish infection in NOD-scid IL2r␥ null mice that lack B cells, T cells, NK cells, and lytic complement. The ospC mutant also could not establish infection in anti-Ly6G-treated SCID and C3H/HeN mice (depletion of neutrophils). However, depletion of mononuclear phagocytes at the skin site of inoculation in SCID and C3H/HeN mice allowed the ospC mutant to establish infection in vivo. In phagocyte-depleted mice, the ospC mutant was able to colonize the joints and triggered neutrophilia during dissemination. Furthermore, we found that phagocytosis of green fluorescent protein (GFP)-expressing ospC mutant spirochetes by murine peritoneal macrophages and human THP-1 macrophage-like cells, but not in PMN-HL60, was significantly higher than parental wild-type B. burgdorferi strains, suggesting that OspC has an antiphagocytic property. In addition, overproduction of OspC in spirochetes also decreased the uptake of spirochetes by murine peritoneal macrophages. Together, our findings provide evidence that mononuclear phagocytes play a key role in clearance of the ospC mutant and that OspC promotes spirochetes' evasion of macrophages during early Lyme borreliosis. L yme disease, the most prevalent vector-borne illness in the United States (1), is a multisystem inflammatory disorder caused by infection with the spirochete Borrelia burgdorferi (2, 3). This spirochete is maintained in nature through a complex enzootic cycle involving Ixodes ticks and various small-mammal hosts. Humans, as accidental hosts, become infected after B. burgdorferiinfected ticks feed on them (4). Spirochetes replicate in the skin, spread locally, and induce an inflammatory response with a symptom known as erythema migrans, observed in most patients (2, 4). During disseminated infection, B. burgdorferi colonizes multiple tissues, leading to different clinical manifestations, including arthritis, myocarditis, and neurological and/or cutaneous abnormalities (2, 4). This acute, disseminated stage of human Lyme disease is largely recapitulated using inbred mouse strains which are susceptible to B. burgdorferi infection and develop carditis and subacute arthritis (5). Thus, the murine model provides a powerful tool to elucidate the role of spirochete virulence factors and host immunological responses during Lyme disease pathogenesis (4).
L
yme disease, the most prevalent vector-borne illness in the United States (1) , is a multisystem inflammatory disorder caused by infection with the spirochete Borrelia burgdorferi (2, 3) . This spirochete is maintained in nature through a complex enzootic cycle involving Ixodes ticks and various small-mammal hosts. Humans, as accidental hosts, become infected after B. burgdorferiinfected ticks feed on them (4) . Spirochetes replicate in the skin, spread locally, and induce an inflammatory response with a symptom known as erythema migrans, observed in most patients (2, 4) . During disseminated infection, B. burgdorferi colonizes multiple tissues, leading to different clinical manifestations, including arthritis, myocarditis, and neurological and/or cutaneous abnormalities (2, 4) . This acute, disseminated stage of human Lyme disease is largely recapitulated using inbred mouse strains which are susceptible to B. burgdorferi infection and develop carditis and subacute arthritis (5) . Thus, the murine model provides a powerful tool to elucidate the role of spirochete virulence factors and host immunological responses during Lyme disease pathogenesis (4) .
The B. burgdorferi genome encodes a large number of surface lipoproteins, many of which are expressed during mammalian infection (4, 6, 7) . One of these lipoproteins is the major outer surface protein C (OspC), whose production is induced within infected nymphal ticks during feeding (8, 9) . OspC continues to be produced during the early phase of infection and is highly immunogenic in mice (10, 11) . As one of the strategies to evade host humoral responses, spirochetes downregulate OspC production in response to anti-OspC antibodies within 2 to 3 weeks after infection in mice (12, 13) . OspC has been shown to be required for B. burgdorferi to establish infection in mammals (8, 14) , as well as for spirochetal transmission from ticks to mammals (15, 16) . Infectivity studies demonstrate that the ospC mutant cannot establish infection in immunocompetent and SCID mice (lacking B and T cells) when inoculated at a dose of 10 3 to 10 5 spirochetes per mouse (8, (16) (17) (18) (19) (20) . The ospC mutant is cleared within the first 48 h of infection in the murine host (21) , suggesting a protective role of OspC against innate defenses. The OspC protective effect in spirochetes seems to be independent of the actions of major antimicrobial peptides (22) . OspC also has been proposed to play roles in promoting survival and/or dissemination of spirochetes within the mammalian host. For example, OspC binds to a tick salivary protein, Salp15, which can protect spirochetes from complementand antibody-mediated killing (23, 24) . OspC was shown to bind host plasminogen (25, 26) , and this phenotype correlates with invasiveness of spirochetes in mice (27) . In addition, constitutive expression of heterologous lipoproteins in the ospC mutant was shown to restore infection in SCID mice, suggesting that OspC may have a nonspecific structural role for B. burgdorferi (14, 19) . On the other hand, another study suggested that the residues within the putative ligand-binding domain are important for OspC function (25) . Despite all research efforts, the precise biological function of OspC during infection remains unclear.
Innate immunity represents the first line of defense against B. burgdorferi infection in mammals (28, 29) . Professional phagocytes, such as monocytes/macrophages and neutrophils, are among the first innate cells that spirochetes encounter during early infection at the skin site of inoculation and target tissues, such as the heart or joints, in mammals (30) (31) (32) . These phagocytes are essential in controlling the spirochetal burden in tissues and directing the development of adaptive immune responses during infection in the murine host (5, 33, 34) . Phagocyte recognition of B. burgdorferi is initiated by multiple Toll-like receptors (TLRs), including TLR2/1 heterodimers, which signal through the adaptor molecule MyD88 (myeloid differentiation primary response 88) (28) . In murine models, a deficiency of MyD88 results in markedly elevated B. burgdorferi burdens in tissues compared to those in infected wild-type mice (33, 35) . However, the ospC mutant remained noninfectious in MyD88 Ϫ/Ϫ mice (36) . Despite the understanding of the immune mediators that modulate host defense and inflammation in the murine model of Lyme borreliosis, the role of professional phagocytes and other innate cells in the clearance of the ospC mutant has not been examined.
In this study, we examined the role of OspC in the protection of spirochetes against innate cells using genetic, antibody-mediated, and pharmacological approaches. We found that the ospC mutant was not able to establish infection in NODSCID-IL2r␥ null and anti-Ly6G-treated SCID and C3H/HeN mice, indicating that NK cells, lytic complement, and neutrophils are not critical in the clearance of the ospC mutant in vivo. Our results showed that depletion of mononuclear phagocytes at the skin site of inoculation contribute to the clearance of the ospC mutant in SCID and C3H/HeN mice. We further showed that OspC plays a role for B. burgdorferi in macrophage phagocytosis by reducing the uptake of spirochetes by murine and human macrophages. In addition, we showed that spirochetes that overexpress OspC exhibit decreased uptake by murine macrophages. Together, our findings show that OspC protects B. burgdorferi strains from mononuclear phagocytes by promoting spirochetes' evasion of these innate cells during early infection in mammals.
MATERIALS AND METHODS
Bacterial strains and culture conditions. B. burgdorferi strain B31-A3 and the isogenic ospC mutant and the ospC-complemented strains were kindly provided by P. Rosa and K. Tilly (Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health) (17) . AH130 is an infectious low-passage strain derived from wild-type strain 297 (37) . The ospC mutant and the ospAB mutant generated in the background of B. burgdorferi strain 297 were reported previously (15, 38) . Spirochetes were grown using standard Barbour-StoennerKelly II (BSK-II) medium containing the relevant antibiotic. Cultures were maintained at 37°C and pH 7.5 in a 5% CO 2 incubator and were passaged no more than three times from the original stocks. To measure growth rate of spirochetes, cells were cultured in BSK-II medium at 37°C and pH 7.5 or pH 6.8. The cell density of cultures was monitored by counting spirochetes under a dark-field microscope (Olympus America Inc., Center Valley, PA).
Generation of GFP-expressing B. burgdorferi strains and the ospAB ospC double mutant. Wild-type B. burgdorferi strain B31-A3 or AH130 and the isogenic ospC mutants were transformed with the shuttle vector pTM61 (generously provided by G. Chaconas, University of Calgary), which harbors a gene encoding GFP under the control of a constitutive flaB promoter from B. burgdorferi (39) . The same shuttle vector (pTM61) was used to transform ospAB and ospAB ospC mutant strains in the 297 background to generate GFP-expressing spirochetes. To generate an ospAB ospC double mutant, an ospAB mutant derived from AH130 strain, XY326 (38, 40) , was transformed with a suicide vector pOspC-Strep plasmid (pXY302) that carries the aadA1 cassette (which confers streptomycin resistance) (15) . Electrotransformation of B. burgdorferi strains was performed as previously described (38) . Selection for transformants was from cultures plated in a 96-well tissue culture plates (200 l/well) containing liquid BSK-II medium and relevant antibiotic markers (50 g ml Ϫ1 gentamicin, 200 g ml Ϫ1 kanamycin, 50 g ml Ϫ1 streptomycin, and 50 ng ml Ϫ1 erythromycin). Positive wells containing transformants were identified by a color change of the medium, and the presence of fluorescent spirochetes was confirmed with an Axio Imager A2 fluorescence microscope (Carl Zeiss, Jena, Germany). The complemented ospC mutant carrying the GFP gene was obtained by transforming the ospC mutant with pTM61-derived shuttle vector carrying both a GFP gene and a wildtype ospC gene (pSEC002; primers used to generate this construct are listed in Table S1 in the supplemental material). Transformants were visualized by fluorescence microscopy and subjected to Western blot analyses to verify the restoration of OspC (ospC-gfp flgBp-ospC). Plasmid profiles were performed for both the ospC mutant and the complemented strains, and they were identical to what was previously reported for the ospC mutant (15, 17) .
Protein electrophoresis and immunoblotting. SDS-PAGE and immunoblotting were performed as previously described (41) . Monoclonal antibodies directed against OspC, OspA, and the loading control FlaB were described previously (42) , and dilutions of 1:2,000, 1:2,000, and 1:500, respectively, were used in this study.
Cell lines. The J2 retrovirus-infected alveolar macrophage cell line (AMJ2-C11) was purchased from the ATCC and grown in Dulbecco's modified Eagle's medium (DMEM) complete culture medium, as described previously (43) . The human monocytic cell line THP-1 was kindly provided by J. Blum (Indiana University School of Medicine) and cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, and 1% penicillin-streptomycin solution. Cells were passaged every 3 to 4 days in fresh RPMI medium. THP-1 cells were differentiated into macrophage-like cells by culturing with 100 nM phorbol myristate acetate (PMA) in RPMI medium for 3 days as previously described (44) . PMA-treated THP-1 cells were rested in fresh RPMI for 4 days more before they were used for phagocytosis assays. PMA-treated THP-1 cells were detached from the flask with nonenzymatic cell dissociation solution (Sigma-Aldrich, St. Louis, MO). HL60 human promyelocytic cell line was kindly provided by H. Broxmeyer (Indiana University School of Medicine) and differentiated into neutrophil-like cells (PMN-HL60) by culturing with 1.25% (vol/vol) dimethyl sulfoxide (DMSO) in DMEM for 6 days as previously described (45) .
Isolation and immortalization of inflammatory peritoneal macrophages. Elicited murine macrophages from C57BL/6 mice were collected by peritoneal lavage with phosphate-buffered saline (PBS) 4 days after the injection of 4% thioglycolate, as described previously (46) . Cells were resuspended in DMEM-conditioned medium containing 10% FBS, 10 mM HEPES, 10 ng macrophage colony-stimulating factor (M-CSF), and 1% penicillin-streptomycin-amphotericin B solution (HyClone; Thermo Scientific, Rockford, IL) and incubated in a 6-well plate (Costar, Cambridge, MA) for 12 h at 37°C with a 5% CO 2 . Nonadherent cells were removed by washing the monolayers with warm serum-free medium. Adherent peritoneal macrophage monolayers were infected with the supernatants of the J2-infected cell line producing oncogenic retrovirus and mixed with DMEM-conditioned medium and 1 g/ml Polybrene (Santa Cruz Biotechnology, Dallas, TX). After 24 h, cells were infected with a second treatment of J2 virus under the same conditions to improve transfection efficiency. Immortalized peritoneal macrophages (PMs) were ob-tained about 4 weeks later and isolated using a previously described method (43) . Residential peritoneal macrophages from C57BL/6 mice were isolated and cultured as previously described (47) .
Mouse strains and inoculation with B. burgdorferi strains. NODscid IL2r␥ null mice (designated NODSCIDg mice here) were acquired from either Jackson Laboratories (Bar Harbor, ME) or the In Vivo Therapeutics Core at the Indiana University Simon Cancer Center (Indianapolis, IN). C.B-17 scid and C3H/HeN mice were acquired from either Harlan Laboratories (Indianapolis, IN) or Taconic Laboratories (Germantown, NY). Some C.B-17 scid mice (designated SCID mice here) and C3H/HeN mice were also from a breeding colony maintained at the Laboratory Animal Research Center (LARC) at the Indiana University School of Medicine. Mice were housed under specific-pathogen-free conditions at LARC.
For mouse infection, groups of 4-to 6-week-old C3H/HeN, SCID, and NODSCIDg were inoculated intradermally (i.d.) at the base of the tail, intraperitoneally (i.p.), or intravenously (i.v.) with a dose of either 10 3 or 10 5 spirochetes per mouse, as indicated for each experiment. Mice were euthanized at specified time points ranging from 2 days to 6 weeks postinoculation. All experiments were performed with the approval of the Indiana University Institutional Animal Care and Use Committee.
Infectivity was assessed weekly by culturing ear punch biopsy specimens in BSK-II medium supplemented with relevant antibiotic markers used to select each strain as well as the Borrelia antibiotic cocktail (50 g ml Ϫ1 rifampin, 20 g ml Ϫ1 phosphomycin, and 2.5 g ml Ϫ1 amphotericin B). Cultures were evaluated for the presence of spirochetes by darkfield microscopy for up to 4 weeks before being designated negative. A single growth-positive culture occurred within 1 to 3 weeks postharvest and was used as the criterion to determine positive mouse infection.
Fluorometric phagocytosis assay. Murine PMs and PMA-treated THP-1 cells were seeded at a density of 3 ϫ 10 5 cells/well in groups of 5 in 96-well tissue culture plates with opaque sides and optically clear bottoms (Costar, Corning Life Sciences, NY). On the following day, a subset of wells were preincubated for 30 min with phagocytosis inhibitor, cytochalasin D (5 g/ml; EMD Chemicals, Gibbstown, NJ) before phagocytosis assays. PMs or PMA-treated THP-1 cells were challenged with GFP-expressing spirochetes at a multiplicity of infection (MOI) of 100:1 and coincubated at 37°C with 5% CO 2 for 2 h. Trypan blue (0.2%; SigmaAldrich) was added for 5 min to quench the fluorescence of extracellular bacteria, and fluorescence was determined using a Spectramax Gemini EM microplate fluorometer (Molecular Devices, Sunnyvale, CA) at excitation and emission wavelengths of 485 and 535 nm, respectively. The phagocytic index (PI) represents the fluorescence of intracellular spirochetes phagocytosed by macrophages and is expressed in relative fluorescence units as previously described (48) . The PI was calculated by subtracting the fluorescence of extracellular spirochetes from cytochalasin D-treated wells from the total fluorescence of the experimental samples.
Flow cytometry. GFP-expressing spirochetes were harvested for phagocytosis assays as described above. Murine PMs, PMA-treated THP-1 cells, or PMN-HL60 cells were challenged with GFP-expressing spirochetes at an MOI of 100:1 for 2 h. Cells were washed twice in fluorescence-activated cell sorting (FACS) buffer (1ϫ PBS, 2 mM EDTA, and 0.5% fetal calf serum [FCS] ) and then fixed in FACS buffer containing 1% paraformaldehyde. Samples were analyzed using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA). To estimate the percent GFPpositive macrophages, cells were gated by forward and side scatter properties, and GFP-positive cells were identified in the FL1 channel. For flow cytometry studies using murine resident peritoneal macrophages, B. burgdorferi-infected cells were incubated with anti-CD16/32 (clone 93) antibodies to block the Fc receptor (eBioscience, San Diego, CA), followed by phycoerythrin (PE)-conjugated anti-mouse F4/80 (clone BM8 at a 1:200 dilution) antibodies (eBioscience). After incubation for 20 min on ice, macrophages were washed in FACS buffer and then fixed for flow-cytometric analysis. Macrophages were gated according to their expression of F4/80 antigen and identified in the FL2 channel. Cells labeled with PEconjugated rat IgG2a (eBioscience) were used as isotype controls. Uptake of GFP-expressing spirochetes by residential macrophages was expressed as the increase in green fluorescence of F4/80 ϩ cells. Unstained cells (without GFP-expressing spirochetes) were used as negative controls for these assays. Cell debris interpreted as dead cells was excluded from analysis. Data were analyzed with Cellquest (BD Biosciences) software, and histograms were edited in FlowJo software (Tree Star, Ashland, OR).
Confocal and immunofluorescence microscopy. Murine PMs were seeded as described above and allowed to adhere to the surface of etched microscope cover slides for 4 h. PMs were then challenged with GFPexpressing spirochetes at an MOI of 100:1 and coincubated at 37°C in RPMI with 10% FBS for 2 h. Infected cells were then washed 4 times with warm PBS, fixed with 4% PFA, permeabilized with 0.1% saponin, and incubated with phalloidin conjugated with CruzFluor 647 (Santa Cruz) for F actin staining. Samples were then mounted on glass slides using ProLong Gold antifade reagent (Life Technologies, Carlsbad, CA) containing 4=,6-diamidino-2-phenylindole (DAPI) dye for cell nucleus DNA staining. Confocal imaging was performed on a Leica SP8 MP confocal microscope (Leica Microsystems Inc., Buffalo Grove, IL) at the Indiana Center of Biological Microcopy core facility. z-stack images were acquired using a 100ϫ oil immersion objective at a pixel resolution of 512 by 512. Image analysis and maximum intensity projections were performed with Fiji software (Life-Line, version of 2 June 2014). Fluorescence images of infected murine PMs were obtained using a Leica DMLB fluorescence microscope (Leica Microsystems Inc.).
In vivo phagocyte depletions. Dichloromethylene diphosphonate (clodronate) encapsulated in liposomes (clodronate liposomes) were purchased from www.clodronateliposomes.org (Vrije University, Amsterdam, The Netherlands). To deplete phagocytes in the skin, 50 l of clodronate liposomes or PBS-containing liposomes (PBS liposomes, used as controls) were i.d. injected into mice 48 and 24 h before challenge with B. burgdorferi strains at the same treatment site. SCID and C3H/HeN mice were then i.d. and i.p. (150 l) injected with either clodronate or PBS liposomes after 24 h postchallenge. In order to reduce recruitment of monocytes to the skin, mice were i.p. injected with either clodronate or PBS liposomes 48 h and 96 h postchallenge (49) .
For neutrophil depletion studies, we used the anti-Ly6G antibody method (clone 1A8; Bio-X-Cell, West Lebanon, NH), which effectively induces neutropenia in mice (50, 51) . Briefly, groups of SCID and C3H/ HeN mice were treated with intraperitoneal injections of 250 g/dose of anti-Ly6G 24 h and 2 h before wild-type B31 or ospC mutant challenge and 24 h postchallenge. As a comparison control group, SCID mice were injected with three doses of 250 g each of isotype antibody rat IgG 2a (clone R35-95; BD Biosciences, San Jose, CA) or control rat IgG (Sigma-Aldrich).
Quantitative PCR. For quantification of B. burgdorferi DNA in tibiotarsal joints, total DNA was extracted from joint tissue using a DNeasy blood and tissue kit as described in the manufacturer's protocols (Qiagen, Valencia, CA). PCR quantification genomic DNA was performed using the RT 2 SYBR green ROX qPCR Mastermix (Qiagen). The oligonucleotide primer pairs used to detect flaB and Nidogen were flaB-XF F (forward)/flaB-XF R (reverse) and Nidogen F (forward)/Nidogen R (reverse), respectively (see Table S1 in the supplemental material) (38, 52) Reactions were carried out on an ABI Prism 7000 real-time PCR machine (Applied Biosystems, Pleasanton, CA). Calculations of DNA copy numbers of flaB were normalized with the copy numbers of the mouse Nidogen gene in each sample.
Leukocyte counts, histology, and immunohistochemistry (IHC). Peripheral blood from mice was collected by cardiac puncture after carbon dioxide narcosis. Complete leukocyte counts with differentials were performed using the hematology analyzer Hemavet 950FS (Drew Scientific, Oxford, CT).
For histology, skin sections (site of inoculation) were collected via 8-mm punch biopsy (Acuderm, Fort Lauderdale, FL) and fixed in 4% paraformaldehyde. Tissues were embedded in paraffin, sectioned at 5 m, and stained with hematoxylin and eosin (H&E). Sections were viewed on a Leica DM3000 microscope (Leica Microsystems Inc.).
Immunohistochemical staining for F4/80 ϩ cells were performed at the IHC core facility at Indiana University School of Medicine. Briefly, antigen retrieval was carried out in a Dako PT module using low-pH retrieval buffer (Dako, Carpinteria, CA). Sections were incubated with rat antimouse F4/80 antibody at a 1:100 dilution (AbD Serotec, Raleigh, NC) and subsequently incubated with biotinylated donkey anti-rat antibody at 1:100 dilution (Jackson ImmunoResearch, West Grove, PA). Detection was accomplished using the LSAB2 method (Dako). Of note, the F4/80 monoclonal antibody has been widely used to detect mature tissue macrophages in mice (53, 54) . Thus, murine macrophages from a spleen section were used as positive controls.
To perform quantitative analysis of F4/80-stained sections, slides were scanned with an Aperio whole-slide digital imaging system (ScanScope CS; Aperio Technologies, Inc., Vista, CA). Skin sections were analyzed using the ImageScope positive pixel count algorithm. The default parameters of the positive pixel count (hue of 0.1 and width of 0.5) were used to detect F4/80 ϩ cells in sections. Data were collected by counting the number of strongly positively staining cells per high-power field and then averaging the results for three randomly selected regions (with a fixed region width of 300 pixels and height of 300 pixels) per skin section.
Similar skin sections (site of inoculation) were evaluated by WarthinStarry staining and indirect IHC for the presence of B. burgdorferi using a previously described method (55, 56) . Sections were incubated for 12 h at 4°C with a 1:1,000 dilution of a polyclonal immune serum from B. burgdorferi-immunized rabbits (generously provided by Stephen Barthold, University of California, Davis).
Statistics. Data are presented as means and standard errors of the means (SEM) and were analyzed with the Prism 5.0 statistical program (GraphPad Software). Comparisons among groups were performed with one-way analysis of variance (ANOVA) followed by a post hoc test, as indicated in the figure legends. Comparisons between two experimental groups were analyzed by Student's t test. A P value of Ͻ0.05 was considered significant.
RESULTS
The ospC mutant cannot establish infection in NODSCIDg mice deficient in lytic complement and NK, B, and T cells. Previous studies have shown that the ospC mutant cannot establish infection in C3H/HeN and SCID mice, which lack functional T and B cells (8, 17, 19, 21) , suggesting that innate immunity is involved in clearance of ospC mutant spirochetes in mice. To investigate which innate factors are involved in clearance of the ospC mutant in vivo, we examined the infectivity of the ospC mutant in another mouse strain, NODSCIDg, which is deficient in T and B cells, as well as lacking complement C5 and functional NK cells (57) . Loss of C5 prevents the activation of C5b and thereby inhibits the formation of the C5b-9 membrane attack complex (57, 58) . Groups of NODSCIDg mice were i.d. injected with either wild-type B31-A3 or the ospC mutant. We used an inoculum of 10 3 spirochetes per mouse, as previously reported (8, 17, 21, 59) . NODSCIDg mice were also inoculated intravenously to assess whether the injection site plays a role in the infectivity of the ospC mutant. As controls, groups of SCID and C3H/HeN mice were also challenged with the wild type or the ospC mutant. Whereas wild-type B31-A3 spirochetes were readily detectable in all tested tissues from NODSCIDg, SCID, and C3H/HeN mice after 3 weeks postchallenge, no ospC mutant spirochetes were detected in tissues from mice inoculated with 10 3 spirochetes per mouse (Table 1) . This result is similar to results of previous studies with immunocompetent and SCID mice (8, 17, 19) . The ospC mutant was not infectious in NODSCIDg mice even after 6 weeks postinoculation (data not shown), regardless of the route of inoculation. These results suggest that, in addition to lymphocytes, innate components such as lytic complement and NK cells are not the major factors that eliminate the ospC mutant in vivo.
Establishment of dose and vehicle for inoculation to study the ospC mutant in vivo. Since NODSCIDg mice have defective functions in different innate cells, we chose an immunodeficient model with an intact innate immune system, such as SCID mice, to assess the role of innate cells in clearance of the ospC mutant. To establish a system to study the ospC mutant in SCID mice, the infectious dose and the vehicle to deliver spirochetes were evaluated in a series of infectivity experiments. Spirochetes used in the infectivity studies described above were used to inoculate mice using BSK-II growth medium, which is a commonly used vehicle to test infectivity of B. burgdorferi strains and mutants in mice. Since BSK-II is a complex medium with 6% rabbit serum and 5% BSA (60) , which may alter the host immune response at the skin site of spirochetal inoculation, we next tested whether the ospC mutant can establish infection using a minimal-medium vehicle, such as PBS buffer. We also compared two routes of inoculation, the intradermal and intraperitoneal routes.
Groups of SCID mice were injected with an inoculum of 10 5 of either B31-A3 or ospC mutant spirochetes per mouse. We increased the inoculum size to 10 5 spirochetes, since the use of PBS or saline could affect viability of spirochetes, based on our preliminary infectivity experiments (data not shown). Similar to the infectivity experiments described above, the ospC mutant were not detected by culture in all harvested tissues from SCID mice when 10 5 spirochetes were injected per mouse, regardless of the vehicle (PBS buffer or BSK-II medium) or the route of inoculation (i.d. or i.p.) (Table 2 ). Thus, we chose an inoculum of 10 5 spirochetes with PBS as a vehicle to explore the interaction of OspC-lacking spirochetes with innate host factors in vivo.
Phagocytes contribute to the clearance of the ospC mutant at the skin inoculation site. The data above, along with previous studies by others (8, 19, 36) , suggest that B cells, T cells, lytic complement and NK cells were not the major host factors that eliminate the ospC mutant in vivo. We next investigated whether professional phagocytes may play a role in the clearance of the ospC mutant. For this purpose, we chose SCID mice, since they (58, 61) . Groups of SCID mice were treated with clodronate liposome to induce depletion of phagocytes in tissues and challenged with an inoculum of 10 5 of either wild-type, ospC mutant, or ospC-complemented spirochetes. It has been extensively shown that clodronate liposome administration in the skin of mice is an effective method to deplete macrophages in the skin (54, 62) . To verify the depletion of macrophages in clodronate liposome-treated mice, we performed immunohistochemistry on skin sections from each group of animals and quantified the cells that were reactive with antibody against F4/80. F4/80 is a membrane glycoprotein that is abundantly expressed on the surface of resident and activated macrophages. Every macrophage expresses F4/80ϩ, and it has been wildly used as a pan-macrophage marker (53, 63, 64) . Immunostaining of skin sections harvested 7 days postchallenge confirmed a significant reduction of phagocytes in SCID mice treated with clodronate liposomes and challenged with either wild-type, ospC-deficient, or ospC-complemented spirochetes (Fig. 1) . Together, these results are in agreement with previous studies showing that subcutaneous injections of clodronate liposomes effectively deplete macrophages in mouse models of skin disorders (49, 54, 62) .
To determine the effect of phagocyte depletion on the infectivity of the ospC mutant, we examined the presence of spirochetes in various tissues 7 days postchallenge. As expected, the ospC mutant could not infect the SCID mice treated with PBS liposomes (control group) ( Fig. 2A and B) , and the mice had neutrophil counts similar to those of naive uninfected SCID mice (see Fig. S1 in the supplemental material). In contrast, the ospC mutant spirochetes were now able to establish infection in SCID mice treated with clodronate (90% [9/10] ). The ospC mutant was reisolated from skin site of inoculation, heart blood, and/or joints, and the spirochetes were detected by Warthin-Starry staining of spirochetes at the skin site of inoculation in clodronate-treated SCID mice even at day 7 postchallenge (Fig. 2B) . In clodronate-treated mice, the ospC mutant disseminates to tissues distant from the inoculation site, and the dissemination correlated with high neutrophil counts in blood, similar to what is observed in SCID mice infected with wild-type or ospC-complemented spirochetes ( Fig. 2A; also, see Fig. S1 in the supplemental material). Note that a low neutrophil level was observed in SCID mice infected with the ospC-complemented spirochetes before clodronate treatment (see Fig. S1 in the supplemental material), and the reason for this phenomenon is unclear. Nevertheless, these data suggest that macrophages play an important role in clearance of the ospC mutant.
To further investigate the role of phagocytes in killing of the ospC mutant in vivo, C3H/HeN mice were treated with clodronate liposomes and challenged with either wild-type, ospC mutant, or ospC-complemented strains. As expected, the ospC mutant was completely cleared from vehicle-treated C3H/HeN mice at day 7 postchallenge (Fig. 3A) . Similar to what was observed in SCID mice, the ospC mutant was able to establish infection in phagocyte-depleted C3H/HeN mice ( Fig. 3A; also, see Fig. S3 in the supplemental material). This group of mice exhibited high neu- 3 ] within the analyzed region). Data are means and SEM from skin sections (site of inoculation) from three mice per treatment condition. Three separate fixed regions were analyzed per skin section. Student's t test was used to determine the significance of differences between clodronate liposome treatment and PBS liposome treatment for each condition (*, P Ͻ 0.05). trophil counts in blood, which was similar to results for C3H/HeN mice infected with wild-type or ospC-complemented spirochetes ( Fig. 3A; also, see Fig. S2 in the supplemental material). Note that in mice infected with wild-type or ospC-complemented spirochetes, spirochetal dissemination triggered the recruitment of neutrophils in C3H/HeN mice, regardless of clodronate treatment ( Fig. 3A; also, see Fig. S2 in the supplemental material), but eosinophil, basophil, and monocyte counts in the blood of these mice were not altered (data not shown). Thus, macrophage depletion in both SCID and C3H/HeN mice supports the notion that phagocytes contribute to the clearance of the ospC mutant in vivo.
Spirochetal burden in joint tissues was quantified by real-time qPCR analyses at day 7 postinfection in both SCID and C3H/HeN mice. Joints from PBS liposome-treated SCID mice infected with the ospC mutant did not have detectable B. burgdorferi DNA (Fig.  2C) , which was consistent with the culture-negative results ( Fig.  2A) . As expected, PBS liposome-treated SCID mice infected with either the wild-type or ospC-complemented strain had high spirochetal loads in joints. In clodronate-treated mice, the ospC mutant spirochetes were readily detectable; the bacterial load seemed lower than mice infected with wild-type spirochetes, but the difference was not statistically significant (Fig. 2C) . The level of wildtype spirochetes in clodronate-treated SCID mice seems higher than that in PBS-liposome-treated SCID mice, but the difference was not statistically significant (Fig. 2C) . In C3H/HeN mice, clodronate liposome treatment led to significantly higher spirochetal
FIG 2 The ospC mutant disseminates and colonizes F4/80
ϩ phagocyte-depleted SCID mice. (A) Infectivity of wild-type, the ospC mutant, and the complemented (comp) strain (ospC/ospCp-ospC) in mice treated with either clodronate or PBS liposomes (control). The numbers of mice used in each group for the wild-type, ospC mutant, and complemented strains were 9, 10, and 7, respectively. Infectivity for each bacterial strain was determined from cultivation of spirochetes from the skin site of inoculation, heart blood, tibiotarsal, and ear pinna at day 7 postchallenge. (B) A representative Warthin-Starry stain demonstrating the presence of ospC mutant spirochetes at the skin site of inoculation (right, magnification, ϫ40; inset, magnification, ϫ100) from clodronate liposome-treated SCID mice (culture positive, n ϭ 5). Spirochetes were observed in dermis (black arrows) and fasciae underneath skeletal muscle. No ospC mutant spirochetes were detected at the skin site of inoculation (left, magnification, ϫ40) of PBS liposome-treated SCID mice at day 7 postchallenge (culture negative, n ϭ 5). (C) Quantitation of spirochetal burden in tibiotarsal joints of clodronate-treated mice. The isolated DNA was subjected to quantitative PCR (qPCR) analyses for the B. burgdorferi flaB gene and the mouse Nidogen gene. Data are representative of two separate experiments, and each black line indicates the mean for 7 to 10 mice in each group. Comparisons of PBS-and clodronate-treated animals were performed using unpaired Student's t test with Welch's correction (***, P Յ 0.0005; *, P Յ 0.05; NS, not significant).
FIG 3 The ospC mutant disseminates and colonizes F4/80
ϩ phagocyte-depleted C3H/HeN mice. (A) Infectivity of the wild-type, ospC mutant, and complemented strains (ospC/ospCp-ospC) in mice treated with either clodronate or PBS liposomes (control). Six mice were used for each treatment group. Infectivity for each bacterial strain was determined from cultivation of spirochetes from the skin site of inoculation, heart blood, tibiotarsal joint, and ear pinna at day 7 postchallenge. (B) Quantitation of spirochetal burden in tibiotarsal joints of clodronate-treated mice. The isolated DNA was subjected to quantitative PCR (qPCR) analyses for the B. burgdorferi flaB gene and the mouse Nidogen gene. Data are means for five to six mice in each group. Comparisons of PBS-and clodronate-treated animals were performed using Student's t test with Welch's correction (**, P Յ 0.01; *, P Յ 0.05; NS, not significant). 3B) . Collectively, these data support the infection results showing that phagocytes were important in the clearance of the ospC mutant at day 7 postinfection in both SCID and C3H/HeN mice.
Treatment of mice with neutrophil-depleting antibody does not restore infectivity of the ospC mutant. Since neutrophils are recruited to the sites of spirochetal infection in mice (29, 30) , we investigated the role of neutrophils in clearance of the ospC mutant. When mice were treated with a monoclonal antibody (antiLy6G) that specifically binds to Ly6G for neutrophil depletion in vivo, we found a significant reduction of circulating neutrophils in SCID and C3H/HeN after 48 h postchallenge with the ospC mutant (see Fig. S4 in the supplemental material). When mice were challenged with the wild-type B31-A3 strain, spirochetes were reisolated from the skin site of inoculation and blood in anti-Ly6G and IgG-treated mice (Table 3) . However, the ospC mutant was not able to survive at the skin site of inoculation and establish infection in anti-Ly6G and isotype IgG antibody control-treated SCID or C3H/HeN mice after the first 48 h (Table 3 ) and 7 days (data not shown) postchallenge. Together, these results indicate that depletion of neutrophils during the first 48 h postchallenge is not sufficient to restore the infectivity of the ospC mutant in vivo.
Abrogation of OspC increases phagocytosis by murine macrophage. The above observation that macrophages play a role in clearance of the ospC mutant prompted us to assess the interaction of phagocytes with spirochetes. We first generated GFP-expressing wild-type, ospC mutant, and ospC-complemented spirochetes. The immunoblotting results showed that both GFP-expressing wild-type and complemented strains (B31 and 297) were not defective in OspC expression (see Fig. S5 and S6 in the supplemental material). In addition, in vitro growth analysis showed that the GFP-expressing ospC mutant spirochetes were motile and exhibited a growth pattern similar to that of the GFP-expressing wildtype (B31) spirochetes when cultivated under various growth conditions (see Fig. S6 in the supplemental material) .
Given that phagocytosis is a critical innate mechanism that macrophages employ to eliminate invading spirochetes (28), we focused on the role of OspC in macrophage phagocytosis using a fluorometry-based method which allows quantification of fluorescence of internalized microorganisms in macrophages (48, 65, 66) . We found that the ospC mutant had approximately 75% higher phagocytosis by murine PMs than the wild-type and the ospC-complemented strains (Fig. 4A, left) . Preliminary experiments were conducted at an MOI of 10:1 (data not shown), and assays at an MOI of 100:1 had the greatest effect on phagocytosis of the ospC mutant. We also confirmed this finding by using another ospC mutant generated in B. burgdorferi strain 297 (15) (Fig. 4A,  right) . Furthermore, we performed the flow cytometry experiment to confirm this finding, which showed that the ospC mutant had approximately 70% higher uptake by murine PMs than the parental wild-type spirochete (Fig. 4B) .
We further visualized the enhanced uptake of the ospC mutant in murine PMs, we assessed fixed specimens of B. burgdorferi strains in contact with macrophages using immunofluorescence and confocal microscopy. When macrophages were coincubated with the GFP-expressing spirochetes for 2 h, uptake of the ospC mutant by PMs was enhanced compared to that of cells incubated with either the wild-type or ospC-complemented strain (see Fig.  S7 in the supplemental material). When individual cells were examined, ospC spirochetes were attached to the surfaces of macrophages, enwrapped by macrophage filamentous structures and internalized in the form of fluorescent blebs or degraded amorphous fluorescent material (Fig. 4C) . Fluorescent blebs or degraded fluorescent material associated with PMs was markedly decreased in cells infected with wild-type spirochetes (Fig. 4C ).
To further demonstrate that OspC plays a role in preventing phagocytosis by macrophages, we isolated resident peritoneal macrophages and then performed a phagocytosis assay to analyze the percentage of GFP-expressing spirochetes ingested by macrophages by FACS analysis. We found that the population of doublepositive F4/80 (marker for macrophage)-and GFP-expressing ospC mutant cells was significantly higher than the population of double-positive cells infected with the GFP-expressing wild-type strain (Fig. 4D) . Collectively, these data suggest that spirochetes expressing OspC have an antiphagocytic property.
Abrogation of OspC increases phagocytosis by human macrophages. We examined whether spirochetes expressing OspC influence phagocytosis in human macrophage-like cells. To test this, human monocytic THP-1 cells were treated with PMA for differentiation into macrophages (44) and then used to assess phagocytosis of GFP-expressing B. burgdorferi strains. THP-1 human macrophage cells express an F4/80 human ortholog termed EMR1 (EGF [epidermal growth factor] module-containing, mucin-like hormone receptor 1) (67, 68) . Using a fluorometric assay and FACS for phagocytosis, we found that the ospC mutant had significantly higher phagocytosis by PMA-treated THP-1 cells than the wild-type and the complemented spirochetes ( Fig. 5A and B) , similar to what was observed for mouse macrophages. We also tested whether human neutrophil-like cells have a similar function, since neutrophil is another type of professional phagocyte that can avidly phagocytose B. burgdorferi (69, 70) . The result showed that uptake of the ospC mutant by human neutrophils was similar to that of the parental wild-type strain (Fig. 5C ), indicating that OspC does not play a role in inhibiting neutrophil-mediated phagocytosis of spirochetes. Thus, results from both murine and human macrophages suggest that OspC has an antiphagocytic property that inhibits macrophage-mediated phagocytosis of spirochetes.
Overproduction of OspC decreases phagocytosis by macrophage. The data above demonstrate that deletion of ospC led to an increased phagocytosis by macrophage. To gain additional evi- a All mice were infected with B. burgdorferi at a dose of 10 5 and euthanized at 48 h postinoculation. Isolation of spirochetes was attempted from the skin site of inoculation, ear pinna, tibiotarsal joint, and heart blood.
dence showing that OspC plays a role in the uptake of spirochetes by macrophages, we further investigated whether overproduction of OspC would result in reduced uptake of spirochetes by macrophage. Previously, we demonstrated that an ospAB mutant in B.
burgdorferi strain 297 overproduces OspC (Fig. 6A) (40) . Accordingly, the ospAB mutant and the ospAB ospC double mutant were subjected to phagocytosis assays. The result showed that the ospAB mutant had markedly reduced uptake by murine PMs (Fig. 6B) . The left image shows wild-type spirochetes (strain 297) associated with a macrophage. The arrowhead indicates a bright green fluorescent bleb that appears to be internalized in a macrophage, and the arrow indicates a cell surface-associated spirochete which is mainly extracellular. The right image shows ospC mutant spirochetes (strain 297) associated with a macrophage. The arrowheads indicate bright fluorescent blebs that appear to have been recently internalized and/or fully degraded into a macrophage, and the arrow indicates a cell surface-associated spirochete which is in the process of being phagocytosed. Cell nucleus DNA (cyan in overlay) was stained with DAPI, and F actin (red in overlay) was stained with phalloidin (bar, 10 m). Deletion of ospC in the ospAB mutant significantly increased phagocytosis of spirochetes by murine macrophages (Fig. 6B) . These results complement the results obtained from the ospC mutant, further supporting the notion that OspC facilitates B. burgdorferi to resist phagocytosis by macrophages.
DISCUSSION
The B. burgdorferi genome encodes numerous surface lipoproteins essential for the pathogen's successful maintenance in the enzootic life cycle (4, 7). OspC is a major surface lipoprotein that is essential for the enzootic cycle of B. burgdorferi (8, (15) (16) (17) 21) . Although it has been proposed that OspC protects spirochetes against innate host defenses (14, 36), the mechanism how OspC contributes to such function remains elusive. In this study, we provide evidence showing that macrophages, not other components of innate immune system such as NK cells, lytic complement, or neutrophils, play a key role in the clearance of the ospC mutant from the skin of SCID and C3H/HeN mice during early infection. Our data showed that OspC protects spirochetes from phagocytosis by macrophage, which contributes to immune evasion of B. burgdorferi during the early stage of mammalian infection.
Both innate and adaptive immune responses are important to control spirochetal burden in the murine host (33, 34) . Previous work has shown that the OspC-deficient spirochetes generated from different B. burgdorferi strain backgrounds cannot establish infection in both immunocompetent and SCID mice, indicating that adaptive immunity does not play a major role in eliminating the ospC mutant infection in vivo (8, 19) . SCID mice have elevated levels of lytic complement activity and normal levels of NK cell activity (58) . In this study, we further investigated NODSCIDg mice, since they lack not only adaptive immunity but also lytic complement and NK cells and also have impaired cytokine signaling due to the lack of the interleukin 2 receptor common gamma chain (IL-2R␥ null ) (57) . Our results showed that the ospC mutant also was not able to establish infection in NODSCIDg mice when inoculated at the standard dose (10 3 spirochetes per mouse). The same inoculum of ospC mutant spirochetes cannot cause infection in C3H/HeN and SCID mice, which is what we observed in our infectivity experiments using these mouse strains (8, 17, 21, 59 ). Our findings suggest that the lytic complement and NK cells were dispensable in the clearance of the ospC mutant. These data are consistent with a previous report by Bockenstedt et al. (71) , showing that the fifth component of complement is not required for protection and disease progression of wild-type B. burgdorferi infection in C5-deficient mouse strains. Our results also support the previous observation that depletion of NK cells did not have a major effect on B. burgdorferi burden and dissemination in arthritis-resistant and -susceptible mouse strains (72) . In this study, we focused on professional phagocytes as one of the primary target cells for our depletion studies, as phagocytes were reported to infiltrate the skin site of inoculation or to be elevated systemically in mice infected with B. burgdorferi (59, 73) . Our result showed that the ospC mutant was cleared within the first 48 h postchallenge in neutropenic SCID and C3H/HeN mice. Although previous reports showed that neutrophils effectively control spirochete burden in tissues from mice infected with wildtype spirochetes (74, 75) , our data indicated that neutrophils were not the major factor in clearing the ospC mutant at the skin site of inoculation in mice. This finding is consistent with a previous study showing no differences in neutrophil infiltration in skin biopsy specimens from mice challenged with wild-type or ospC mutant spirochetes (59) . In contrast, we found that depletion of mononuclear phagocytes at the skin site of inoculation in SCID and C3H/HeN mice allowed the ospC mutant to establish infection and dissemination, suggesting that these innate cells were indispensable in clearing the ospC mutant. This result implies that B. burgdorferi employs OspC to resist mononuclear phagocyte killing at the skin site of infection. We also observed an increased spirochete load in joints of clodronate liposome-treated mice, which is consistent with the notion that mononuclear phagocytes are important in controlling B. burgdorferi burden in cardiac tissue and joints of infected mice (30, 33) . However, the spirochete load in joints of clodronate liposome-treated mice infected with the ospC mutant was still lower than the spirochete load from joints of treated mice infected with either the wild-type or ospCcomplemented strain. This observation suggests that either ablation of multiple innate host factors is needed to restore comparable spirochete loads in tissues between the ospC mutant and the wild-type strain or the ospC mutant had a defect in the ability to adapt and replicate in mouse skin, regardless of the innate immune pressure on ospC spirochetes.
Administration of clodronate liposome is an effective approach to deplete mononuclear phagocytes such as macrophages from the skin in mice (54, 62, 76) . One caveat for this approach is that it relies on the mode of action of clodronate bisphosphonate to induce apoptosis inside the cells, which can have an anti-inflammatory effect in tissue milieus and alter the innate cell homeostasis (77, 78) . Although apoptosis was not quantified from skin biopsy specimens used in this study, we observed apoptotic cells on skin sections (data not shown), which may have created a permissive environment for the ospC mutant to survive at the skin site of inoculation in treated mice and may also indirectly contribute to the ospC mutant to establish infection in mice. The role of ingestion of spirochete-infected apoptotic cells in the clearance of B. burgdorferi remains to be investigated. In addition, although clodronate liposome administration in the skin of mice is an effective and selective method to deplete macrophages in the skin (54, 62) , other phagocytes, including dendritic cells (DCs), may also be depleted. Although we were not able to determine the contribution of DCs to the clearance of ospC mutant, our subsequent in vitro data demonstrated that resident macrophages play an important role in phagocytosis of the ospC mutant.
Human macrophages and murine peritoneal and bone marrow-derived macrophages can efficiently phagocytose and kill B. burgdorferi (79, 80) . In addition, B. burgdorferi encodes complement regulator-acquiring surface proteins (CRASPs), which provides resistance to complement activation that leads to a reduction in phagocytosis (81, 82) . In our phagocytosis assays, we demonstrated significantly higher nonopsonic phagocytosis of the ospC mutant than the wild-type strain using two independent B. burgdorferi infectious strains and murine and human macrophages. We also incubated macrophages with recombinant OspC prior to the phagocytosis assay but did not observe a reduction in the uptake of spirochetes by murine peritoneal macrophages (data not shown). One possible explanation is that recombinant OspC is not lipidated. Unfortunately, expressing lipidated recombinant OspC is technically challenging, and we have not been able to obtain such a protein. Another possible explanation is that recombinant OspC may not be folded correctly and may therefore fail to be recognized by a phagocytic receptor. burgdorferi strain 297, the isogenic ospC, ospAB (constitutively expressing ospC), and ospABC mutants, and the ospC-complemented strain were cultivated in BSK-II medium (pH 7.5) at 37°C. Spirochetes were harvested at a density of 10 8 cells/ml, and then whole-cell lysates were separated by SDS-PAGE and subjected to immunoblot analysis using a mixture of antibodies against FlaB (control), OspA, and OspC. (B) Phagocytosis of GFP-expressing wild type and the isogenic ospAB and ospABC mutants by murine PMs was measured with a microplate fluorometer. PMs were incubated with GFP-expressing spirochetes at an MOI of 100 for 2 h. The phagocytic index (PI) represents the fluorescence of intracellular bacteria phagocytosed by macrophages and was calculated as described in Material and Methods. Data are representative of 4 or 6 separate experiment with at least 4 replicates per experiment and are expressed as a percentage of phagocytosis of wild-type spirochetes (control). Values are means and SEM. Comparisons among experimental groups were performed with one-way ANOVA followed by Dunnett's post hoc test and Student's t test (*, P Ͻ 0.05).
To obtain additional evidence that OspC is involved in phagocytosis, we examined the phagocytosis of an B. burgdorferi strain that constitutively overproduces OspC, the ospAB mutant. OspA and OspB are two proteins encoded by a single operon on linear plasmid 54 (83) and are primarily expressed in the tick vector but repressed during a blood meal, when spirochetes prepare to infect mammals (38, 84, 85) . We previously generated an ospAB mutant of strain 297 that constitutively produces high level of ospC. This ospAB mutant strain remained infectious and caused arthritis in mice (38) . We found that this strain was significantly less phagocytosed by murine peritoneal macrophages, which further supports previous reports showing that OspC has a protective role in spirochetes facing innate defenses in vivo.
In this study, we showed that PMA-differentiated THP-1 cells were highly phagocytic against a B. burgdorferi ospC mutant strain, which is different from a previous study showing that vitamin D 3 -treated THP-1 cells had poor phagocytic capacity for B. burgdorferi (86) . One possible explanation was that we used PMA to activate and differentiate THP-1 cells into macrophage-like cells (87, 88) . PMA-differentiated THP-1 cells have been demonstrated to exhibit higher phagocytic activity and adherence and different expression of surface receptors than vitamin D 3 -differentiated THP-1 cells (44, 88) .
In conclusion, our findings reveal a novel antiphagocytic property for OspC which may facilitate the evasion of spirochetes from mononuclear phagocytes during early mammalian infection. In addition, since OspC is upregulated when spirochetes are in the tick midgut during the process of tick feeding, OspC could protect B. burgdorferi from phagocytosis in the tick vector. Although several major surface proteins of B. burgdorferi have been shown to play roles in interactions with host factors (e.g., DbpB/A, BBK32, and Lmp) (66, 89, 90) , none of these proteins were reported to have the antiphagocytic activity of a major borrelial surface protein. We are currently delineating the underlying mechanism by which OspC affects phagocytosis by macrophage. In this regard, it is known that phagocytosis of B. burgdorferi by macrophages involves several phagocytic receptors (91) (92) (93) and pattern recognition receptors (28, 94) . One possibility is that OspC alters phagocytic receptor profiles upon contact with macrophages. Alternatively, OspC may shield Borrelia ligands from interacting with phagocytosis by macrophage via conventional (28) or coiling phagocytosis (79) . Our findings implicate that mononuclear phagocytes, including macrophages, may serve as a natural barrier contributing to control B. burgdorferi numbers at the skin site of inoculation, which subsequently influences the outcome of spirochetal invasiveness in the murine host.
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